This Euvichol or Euvichol-Plus market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the rising demand for generic UDCA, increased awareness among healthcare professionals, growing awareness of NASH and liver health, a demand for personalized liver health approaches, and the increasing use of pharmaceutical therapies.
The projected growth for the forecast period is driven by the rising prevalence of chronic kidney disease (CKD), an increase in liver fibrosis cases, growing rates of obesity and type 2 diabetes, and a higher prevalence of NASH and non-alcoholic fatty liver disease (NAFLD). Key trends for the forecast period include technological advancements in drug delivery systems, progress in diagnostic technologies, a focus on biopharmaceutical innovations, developments in drug research, and the integration of telemedicine and digital health tools.
The increasing prevalence of liver diseases is expected to drive the growth of the euvichol and euvichol-plus market in the coming years. Liver diseases encompass a variety of conditions that impair the liver’s ability to function properly. The rising rates of obesity, which contribute to non-alcoholic fatty liver disease, and excessive alcohol consumption, a major cause of alcoholic liver disease, are key factors driving this increase. Euvichol and Euvichol-Plus are used to manage liver diseases, particularly chronic hepatitis B, by enhancing liver cell membrane integrity, reducing inflammation, and supporting liver function. For example, according to GOV.UK, a UK-based government agency, hospital admissions for liver disease rose to 155.2 per 100,000 people in the 2023 financial year, up from 150.6 per 100,000 in 2022. This growing prevalence of liver diseases is fueling the market growth of euvichol and euvichol-plus.
The rise in healthcare expenditure is expected to boost the growth of the euvichol and euvichol-plus market in the future. Healthcare expenditure includes the total spending on healthcare services such as hospital care, medical research, pharmaceuticals, public health programs, and other related services. The increase in healthcare spending is driven by factors such as an aging population, higher rates of chronic diseases, medical advancements, and rising treatment costs. This higher expenditure helps improve the distribution and accessibility of Euvichol and Euvichol-Plus, particularly for cholera prevention in vulnerable populations. For instance, a report from the Office for National Statistics in May 2024 indicated a 5.6% rise in healthcare spending from 2022 to 2023, compared to a 0.9% increase in 2022. Additionally, long-term health and social care spending grew by 2.8% in real terms in 2022. As a result, the growth in healthcare expenditure is contributing to the expansion of the euvichol and euvichol-plus market.
A significant trend in the euvichol and euvichol-plus market is the development of advanced technological solutions, such as oral cholera vaccines, to address critical industry needs. Oral cholera vaccines are taken by mouth to protect against cholera, a bacterial infection that causes severe diarrhea and dehydration. In May 2023, Techinvention Lifecare Pvt. Ltd., an India-based biotechnology company, launched Euvichol-Plus, the first oral cholera vaccine packaged in a low-density polyethylene (LDPE) unidose pack. This innovative packaging enhances usability and safety by reducing the risks of breakage and waste commonly associated with traditional glass vials. After successfully completing a Phase III clinical trial, Euvichol-Plus was approved by the Central Drugs Standard Control Organization (CDSCO) and is now addressing a significant public health concern in India, where around 400 million people are at risk of cholera. The vaccine is expected to improve distribution during emergencies and humanitarian crises, supporting global efforts to eliminate cholera by 2030.
Major companies operating in the euvichol or euvichol-plus market are Eubiologics Co. Ltd., and Techinvention Lifecare Pvt. Ltd.
North America was the largest region in the euvichol or euvichol-plus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in euvichol or euvichol-plus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the euvichol Or euvichol-plus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Euvichol and Euvichol-Plus are pharmaceutical products primarily used to treat liver diseases, particularly those associated with cholestasis, gallstones, and primary biliary cirrhosis (PBC). Both medications are based on ursodeoxycholic acid (UDCA), with Euvichol-Plus serving as a combination therapy.
The main products in the Euvichol line include Euvichol and Euvichol-Plus. Euvichol is an oral cholera vaccine primarily used for preventing cholera in areas where the disease is endemic or during outbreaks. It has various clinical indications, including non-alcoholic fatty liver disease (NAFLD), liver dysfunction, detoxification, and liver protection. Euvichol is distributed through hospitals, clinics, pharmacies, and public health campaigns.
The euvichol or euvichol-plus market research report is one of a series of new reports that provides euvichol or euvichol-plus market statistics, including euvichol or euvichol-plus industry global market size, regional shares, competitors with a euvichol or euvichol-plus market share, detailed euvichol or euvichol-plus market segments, market trends and opportunities, and any further data you may need to thrive in the euvichol or euvichol-plus industry. This euvichol or euvichol-plus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The euvichol or euvichol-plus market consists of sales of products including ursofalk, actigall, and generic ursodeoxycholic acid (UDCA) formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the rising demand for generic UDCA, increased awareness among healthcare professionals, growing awareness of NASH and liver health, a demand for personalized liver health approaches, and the increasing use of pharmaceutical therapies.
The projected growth for the forecast period is driven by the rising prevalence of chronic kidney disease (CKD), an increase in liver fibrosis cases, growing rates of obesity and type 2 diabetes, and a higher prevalence of NASH and non-alcoholic fatty liver disease (NAFLD). Key trends for the forecast period include technological advancements in drug delivery systems, progress in diagnostic technologies, a focus on biopharmaceutical innovations, developments in drug research, and the integration of telemedicine and digital health tools.
The increasing prevalence of liver diseases is expected to drive the growth of the euvichol and euvichol-plus market in the coming years. Liver diseases encompass a variety of conditions that impair the liver’s ability to function properly. The rising rates of obesity, which contribute to non-alcoholic fatty liver disease, and excessive alcohol consumption, a major cause of alcoholic liver disease, are key factors driving this increase. Euvichol and Euvichol-Plus are used to manage liver diseases, particularly chronic hepatitis B, by enhancing liver cell membrane integrity, reducing inflammation, and supporting liver function. For example, according to GOV.UK, a UK-based government agency, hospital admissions for liver disease rose to 155.2 per 100,000 people in the 2023 financial year, up from 150.6 per 100,000 in 2022. This growing prevalence of liver diseases is fueling the market growth of euvichol and euvichol-plus.
The rise in healthcare expenditure is expected to boost the growth of the euvichol and euvichol-plus market in the future. Healthcare expenditure includes the total spending on healthcare services such as hospital care, medical research, pharmaceuticals, public health programs, and other related services. The increase in healthcare spending is driven by factors such as an aging population, higher rates of chronic diseases, medical advancements, and rising treatment costs. This higher expenditure helps improve the distribution and accessibility of Euvichol and Euvichol-Plus, particularly for cholera prevention in vulnerable populations. For instance, a report from the Office for National Statistics in May 2024 indicated a 5.6% rise in healthcare spending from 2022 to 2023, compared to a 0.9% increase in 2022. Additionally, long-term health and social care spending grew by 2.8% in real terms in 2022. As a result, the growth in healthcare expenditure is contributing to the expansion of the euvichol and euvichol-plus market.
A significant trend in the euvichol and euvichol-plus market is the development of advanced technological solutions, such as oral cholera vaccines, to address critical industry needs. Oral cholera vaccines are taken by mouth to protect against cholera, a bacterial infection that causes severe diarrhea and dehydration. In May 2023, Techinvention Lifecare Pvt. Ltd., an India-based biotechnology company, launched Euvichol-Plus, the first oral cholera vaccine packaged in a low-density polyethylene (LDPE) unidose pack. This innovative packaging enhances usability and safety by reducing the risks of breakage and waste commonly associated with traditional glass vials. After successfully completing a Phase III clinical trial, Euvichol-Plus was approved by the Central Drugs Standard Control Organization (CDSCO) and is now addressing a significant public health concern in India, where around 400 million people are at risk of cholera. The vaccine is expected to improve distribution during emergencies and humanitarian crises, supporting global efforts to eliminate cholera by 2030.
Major companies operating in the euvichol or euvichol-plus market are Eubiologics Co. Ltd., and Techinvention Lifecare Pvt. Ltd.
North America was the largest region in the euvichol or euvichol-plus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in euvichol or euvichol-plus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the euvichol Or euvichol-plus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Euvichol and Euvichol-Plus are pharmaceutical products primarily used to treat liver diseases, particularly those associated with cholestasis, gallstones, and primary biliary cirrhosis (PBC). Both medications are based on ursodeoxycholic acid (UDCA), with Euvichol-Plus serving as a combination therapy.
The main products in the Euvichol line include Euvichol and Euvichol-Plus. Euvichol is an oral cholera vaccine primarily used for preventing cholera in areas where the disease is endemic or during outbreaks. It has various clinical indications, including non-alcoholic fatty liver disease (NAFLD), liver dysfunction, detoxification, and liver protection. Euvichol is distributed through hospitals, clinics, pharmacies, and public health campaigns.
The euvichol or euvichol-plus market research report is one of a series of new reports that provides euvichol or euvichol-plus market statistics, including euvichol or euvichol-plus industry global market size, regional shares, competitors with a euvichol or euvichol-plus market share, detailed euvichol or euvichol-plus market segments, market trends and opportunities, and any further data you may need to thrive in the euvichol or euvichol-plus industry. This euvichol or euvichol-plus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The euvichol or euvichol-plus market consists of sales of products including ursofalk, actigall, and generic ursodeoxycholic acid (UDCA) formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Euvichol or Euvichol-Plus Market Characteristics4. Euvichol or Euvichol-Plus Market Trends and Strategies5. Euvichol or Euvichol-Plus Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Euvichol or Euvichol-Plus Pricing Analysis & Forecasts30. Global Euvichol or Euvichol-Plus Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Euvichol or Euvichol-Plus Market32. Recent Developments in the Euvichol or Euvichol-Plus Market
3. Euvichol or Euvichol-Plus Market Biologic Drug Characteristics
6. Global Euvichol or Euvichol-Plus Growth Analysis and Strategic Analysis Framework
8. Euvichol or Euvichol-Plus Market Segmentation
9. Global Euvichol or Euvichol-Plus Epidemiology of Clinical Indications
10. Euvichol or Euvichol-Plus Market Regional and Country Analysis
11. Asia-Pacific Euvichol or Euvichol-Plus Market
12. China Euvichol or Euvichol-Plus Market
13. India Euvichol or Euvichol-Plus Market
14. Japan Euvichol or Euvichol-Plus Market
15. Australia Euvichol or Euvichol-Plus Market
16. South Korea Euvichol or Euvichol-Plus Market
17. Western Europe Euvichol or Euvichol-Plus Market
18. UK Euvichol or Euvichol-Plus Market
19. Germany Euvichol or Euvichol-Plus Market
20. France Euvichol or Euvichol-Plus Market
21. Eastern Europe Euvichol or Euvichol-Plus Market
22. North America Euvichol or Euvichol-Plus Market
23. USA Euvichol or Euvichol-Plus Market
24. Canada Euvichol or Euvichol-Plus Market
25. South America Euvichol or Euvichol-Plus Market
26. Middle East Euvichol or Euvichol-Plus Market
27. Africa Euvichol or Euvichol-Plus Market
28. Euvichol or Euvichol-Plus Market Competitive Landscape and Company Profiles
29. Global Euvichol or Euvichol-Plus Market Pipeline Analysis
33. Euvichol or Euvichol-Plus Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Euvichol or Euvichol-Plus Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on euvichol or euvichol-plus market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for euvichol or euvichol-plus? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The euvichol or euvichol-plus market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Product Type: Euvichol; Euvichol-Plus2) by Clinical Indication: Non-Alcoholic Fatty Liver Disease (NAFLD); Liver Dysfunction; Detoxification and Liver Protection
3) by Distribution Channel: Hospitals and Clinics; Pharmacies; Public Health Campaigns
Key Companies Mentioned: Eubiologics Co. Ltd.; Techinvention Lifecare Pvt. Ltd.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Eubiologics Co. Ltd.
- Techinvention Lifecare Pvt. Ltd.
